To assess the reliability of quantitative histomorphometry measurements for the intimal reaction that occurs after intraluminal stenting in an animal model.
Methods:
Two self-expanding intravascular stents, a biodegradable poly-D/L-lactic acid (PLA) stent and a stainless steel Wallstent, were implanted in the common iliac arteries of a beagle dog. After 45 days, the histomorphometry of the stented iliac artery segments was quantitatively measured. The relative standard error (RSE) of the estimate was calculated, and the reliability of measurements for maximal (LDmax) and minimal (LDmin) luminal diameters and internal (IELT) and external (EELT) elastic lamina thicknesses was assessed.
Results:
The PLA stent required more measurements of variables from a single slide to ensure reliable (RSE<10%) results (1 for LDmax, 1 for LDmin, 8 for IELT, and 4 for EELT) compared to the Wallstent (1 for LDmax, 1 for LDmin, 2 for IELT, and 2 for EELT 2). The measured results were reliable for both stent materials when variables were measured from 2 slides of each segment (proximal/central/distal) of the stent.
Conclusions:
We conclude that these preliminary measurements to estimate the reliability of quantitative histomorphometry measurements should be made and reported before final results are given.
FischmanDLLeonMBBaimDS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med.1994; 331: 496–501.
2.
FarbAWeberDKKolodgieFD. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002; 105: 2974–2980.
3.
SerruysPWde JaegerePKiemeneijF. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med.1994; 331: 489–495.
4.
AjaniAEKimHSWaksmanR. Clinical trials of vascular brachytherapy for in-stent restenosis: Update. Cardiovasc Radiat Med.2001; 2: 107–113.
BabapulleMNEisenbergMJ. Coated stents for the prevention of restenosis: Part II. Circulation. 2002; 106: 2859–2866.
7.
BabapulleMNEisenbergMJ. Coated stents for the prevention of restenosis: Part I. Circulation. 2002; 106: 2734–2740.
8.
MoriceMCSerruysPWSousaJE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002; 346: 1773–1780.
9.
LiistroFStankovicGDi MarioC. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long-term clinical and angiographic outcome. Circulation. 2002; 105: 1883–1886.
10.
VirmaniRLiistroFStankovicG. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002; 106: 2649–2651.
11.
van der GiessenWJLincoffAMSchwartzRS. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690–1697.
12.
IsotaloTTaljaMTammelaTL. Cytotoxicity testing of a new caprolactone-coated self-expanding bioabsorbable self-reinforced poly-L-lactic acid urethral stent. Urol Res.1999; 27: 149–152.
13.
IsotaloTAlarakkolaETaljaM. Biocompatibility testing of a new bioabsorbable X-ray positive SR-PLA 96/4 urethral stent. J Urol.1999; 162: 1764–1767.
14.
HietalaEMSalminenUSStahlsA. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res.2001; 38: 361–369.
15.
TamaiHIgakiKTsujiT. A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J Interv Cardiol.1999; 12: 443–450.
16.
TamaiHIgakiKKyoE. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation. 2000; 102: 399–404.
17.
IsotaloTTaljaMHellstromP. A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia. BJU Int.2001; 88: 30–34.
18.
SchwartzRSEdelmanERCarterA. Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation. 2002; 106: 1867–1873.
19.
SchwartzRSHuberKCMurphyJG. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol.1992; 19: 267–274.
20.
KornowskiRHongMKTioFO. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol.1998; 31: 224–230.
21.
MathieuOCruz-OriveLMHoppelerH. Measuring error and sampling variation in stereology: Comparison of the efficiency of various methods for planar image analysis. J Microsc. 1981; 121: 75–88.
22.
NewbyACZaltsmanAB. Molecular mechanisms in intimal hyperplasia. J Pathol.2000; 190: 300–309.
23.
SerruysPWDegertekinMTanabeK. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002; 106: 798–803.
24.
RegarESerruysPWBodeC. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002; 106: 1949–1956.
LincoffAMFurstJGEllisSG. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol.1997; 29: 808–816.
27.
AltEHaehnelIBeilharzC. Inhibition of neointima formation after experimental coronary artery stenting: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation. 2000; 101: 1453–1458.
28.
De ScheerderIWangKWilczekK. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 1997; 95: 1549–1553.
29.
YamawakiTShimokawaHKozaiT. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol.1998; 32: 780–786.
30.
YamagishiMHosokawaHSaitoS. Coronary disease morphology and distribution determined by quantitative angiography and intravascular ultrasound—reevaluation in a cooperative multicenter intravascular ultrasound study (COMIUS). Circ J.2002; 66: 735–740.
31.
PratiFPawlowskiTSommarivaL. Intravascular ultrasound and quantitative coronary angiography assessment of late in-stent restenosis: In vivo human correlation and methodological implications. Catheter Cardiovasc Interv.2002; 57: 155–160.
32.
StrehblowCGyongyosiMSperkerW. Usefulness of intravascular ultrasound-guided histological measurements after stenting in porcine coronary artery. Coron Artery Dis.2002; 13: 291–294.
